KR
Krystal Biotech
KRYS · NASDAQ
$348.09 -0.62% (-$2.16)
1M +6.43%
Market Cap $10.3B
P/E Ratio 42.50x
Div. Yield -
ROE 19.34%
Bulios Fair Price
$248.95
28.5% downside
Current Price
$348.09
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KRYS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
17 /100
Expensive P/E 42.50x
EV/EBITDA 45.06x
P/S 23.30x
Growth
100 /100
Growing Book val. growth 32.67%
EPS growth N/A
Rev. growth N/A
Profitability
100 /100
Strong Gross margin 93.34%
Net margin 54.82%
Op. margin 44.93%
Quality
78 /100
Excellent ROIC 15.34%
ROE 19.34%
ROA 16.09%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 8.32x
Net debt/EBITDA -1.92x
Stability
41 /100
Moderate Beta 0.54x
EPS volatility 318.68%
Profitable years 3
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KRYS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Krish S. Krishnan
Employees
295
Headquarters
Pittsburgh
Upcoming events
02 NOV
Earnings
Upcoming earnings report